Next Article in Journal
Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases
Next Article in Special Issue
The Treatment of Melioidosis
Previous Article in Journal
Lambda Interferons: New Cytokines with Old Functions
Pharmaceuticals 2010, 3(4), 810-838; doi:10.3390/ph3040810
Review

Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase

1,*  and 2,*
Received: 1 February 2010 / Revised: 15 March 2010 / Accepted: 19 March 2010 / Published: 25 March 2010
(This article belongs to the Special Issue Tropical Medicine)
View Full-Text   |   Download PDF [638 KB, uploaded 25 March 2010]   |   Browse Figures

Abstract

Chagas’ disease, or American trypanosomosiasis, has been the most relevant illness produced by protozoa in Latin America. Synthetic medicinal chemistry efforts have provided an extensive number of chemodiverse hits at the “active-to-hit” stage. However, only a more limited number of these have been studied in vivo in models of Chagas’ disease. Herein, we survey some of the cantidates able to surpass the “hit-to-lead” stage discussing their limitations or merit to enter in clinical trials in the short term.
Keywords: Chagas’ disease; “hit-to-lead”; drug-likeness Chagas’ disease; “hit-to-lead”; drug-likeness
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Cerecetto, H.; González, M. Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase. Pharmaceuticals 2010, 3, 810-838.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert